GSK Studies Show No Increased Heart Attack Risk From Abacavir An analysis of 52 studies of abacavir (found in Ziagen, Epzicom and Trizivir) by the drug’s maker, GlaxoSmithKline (GSK), found no increased risk for heart attacks in people taking the drug, according to a study published in the May issue of the Journal of Acquired Immune Deficiency Syndromes. These results stand in contrast to results of other studies finding an increased risk of heart attacks among people on abacavir.
April 29, 2009
Prezista Levels in the Brain High Enough to Control HIV Levels of the protease inhibitor (PI) Prezista (darunavir) are high enough in cerebrospinal fluid (CSF) to control HIV reproduction in the brain, according to a study published in the April issue of AIDS Research and Human Retroviruses. Suppressing HIV in the brain may help prevent thinking and memory problems as people living with the virus age, though this has not been proved in clinical trials.
HIV Positive and Negative Have Equal Liver Transplant Survival Rates
HIV-positive liver transplant recipients are just as likely to be alive both one and five years after a transplant as HIV-negative patients, according to a study presented this week at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, and reported by ScienceDaily.
April 24, 2009
Atripla Co-pay Program Announced Gilead Sciences and Bristol-Myers Squibb (BMS) announced today that they have added the drug Atripla (efavirenz, tenofovir and emtricitabine), which they jointly make and sell, to the list of drugs for which they offer co-payment assistance.
April 23, 2009
New Research Shows Why Antibodies Fail to Control HIV Antibodies produced by the immune system aren’t effective against HIV—and new research potentially explains why. Protein spikes on HIV’s surface are too few and far between for antibodies to adequately latch on to, according to California Institute of Technology researchers reporting their study results in The Proceedings of the National Academy of Sciences and summarized by ScienceDaily.
April 22, 2009
HIV Treatment May Offer Only Partial Heart Protection Antiretroviral (ARV) therapy has a contradictory effect on the risk of heart disease, according to a study published in the April 15 issue of The Journal of Infectious Diseases and reported by aidsmap. While HIV treatment appears to reduce the damaging effects of inflammation on blood vessels, it is also associated with an increased risk of artery-clogging plaques.
April 21, 2009
Isentress’s Prevention Potential The integrase inhibitor Isentress (raltegravir), when taken by either HIV-negative or HIV-positive people, might be able to prevent HIV transmission, according to a presentation at the International Clinical Pharmacology Workshop in Amsterdam.
April 20, 2009
“Quad” HIV Pill Enters Phase II Study Gilead Sciences Inc. announced today it initiated a Phase II study of a new four-in-one—or “Quad”—HIV treatment. The Quad pill includes Gilead’s experimental integrase inhibitor called elvitegravir, an experimental boosting agent called GS 9350 and the approved drugs Viread (tenofovir) and Emtriva (emtricitabine).
April 17, 2009
BMS Launches Co-Pay Assistance Program Bristol-Myers Squibb (BMS) announced today that it is launching its own co-payment assistance program for Reyataz (atazanavir) and Sustiva (efavirenz) starting April 30.
Is Big Pharma Stifling AIDS Research? The pharmaceutical industry is stifling the innovation and development of new treatments for HIV, and those who should be representing the interests of people with HIV are too dependent on pharmaceutical funding to be effective watchdogs, according to an article in Frontiers IN LA magazine.
April 13, 2009
Another Study Recommends Earlier ARV Treatment A second large cohort study has confirmed that starting antiretroviral (ARV) therapy before CD4 counts fall to 350 or below—which is the current guidelines cutoff—protects against developing an AIDS diagnosis and death, according to the authors of a study published online April 9 in The Lancet and reported by aidsmap.
April 10, 2009
Scientists Discover How Herpes Viruses May Lead to Cancer Researchers have discovered that some herpes viruses can reduce the ability of cells to shut themselves down or die, which is critical to halting the development of cancers such as lymphoma and Kaposi’s sarcoma (KS). Their findings are published in the April 2 issue of The EMBO Journal.
April 09, 2009
Leptin Reduces Belly Fat HIV-positive men who were given an experimental version of the hormone leptin had a significant reduction in their belly fat after three months of treatment, according to a study published in the April issue of The Journal of Clinical Endocrinology & Metabolism.
April 08, 2009
Kaletra Might Cause Heart Rhythm Disturbances The U.S. Food and Drug Administration (FDA) has revised the prescribing instructions for the protease inhibitor Kaletra (lopinavir plus ritonavir) to include a new warning about heart rhythm disturbances that might be caused by the drug. While the agency points out that studies haven’t definitely linked Kaletra to these problems, it is nonetheless suggesting that health care providers be cautious when prescribing the drug to anyone with underlying heart problems or to those using other drugs known to cause heart rhythm disturbances.
April 07, 2009
HIV Treatment Alone Is Enough for Most Who Catch KS Early The majority of people who catch AIDS-related cancer Kaposi’s sarcoma (KS) in its earliest stage and quickly begin taking antiretroviral (ARV) therapy may not require treatment with chemotherapy, according to a study presented at the 15th Annual Conference of the British HIV Association in Liverpool and reported by aidsmap.
April 06, 2009
Vitamin D Might Blunt Tenofovir-Associated Bone Problems Vitamin D supplements might protect people taking tenofovir (found in Viread, Truvada and Atripla) from elevated hormone levels, which can lead to bone mineral loss, according to a study presented at the 15th Annual Conference of the British HIV Association in Liverpool and reported by aidsmap.
April 03, 2009
Shorter Duration Hep C Treatment May Be Possible for Some
People with HIV and hepatitis C virus (HCV) and who achieve undetectable HCV levels after only four weeks of HCV treatment may be able to clear HCV after only 24 weeks of treatment, according to a study published April 15 in Clinical Infectious Diseases.
New Drug May Boost HIV Treatment Effectiveness The addition of an experimental amino acid to a standard HIV drug regimen may be all that’s necessary for people struggling to keep their viral loads undetectable, according to a study published in The Journal of Immunology and reported by EurekAlert.
More Treatment News
Have news about HIV? Send press releases, news tips and other announcements to firstname.lastname@example.org.